Cowen and Company Reaffirms “Buy” Rating for Alexion Pharmaceuticals Inc. (ALXN)
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “buy” rating restated by Cowen and Company in a research report issued to clients and investors on Thursday.
A number of other research firms have also weighed in on ALXN. Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Friday, June 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $185.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, May 29th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $221.00 price objective (down previously from $228.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Finally, SunTrust Banks Inc. reduced their target price on Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $182.85.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.58% during midday trading on Thursday, hitting $132.42. 404,941 shares of the stock traded hands. The stock has a 50 day moving average of $131.16 and a 200 day moving average of $135.82. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45. The company has a market capitalization of $29.69 billion, a P/E ratio of 332.71 and a beta of 1.08.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/cowen-and-company-reaffirms-buy-rating-for-alexion-pharmaceuticals-inc-alxn.html
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The company had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. During the same period last year, the business earned $1.44 EPS. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals will post $4.65 earnings per share for the current fiscal year.
In other Alexion Pharmaceuticals news, EVP Carsten Thiel sold 3,225 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total transaction of $414,960.75. Following the sale, the executive vice president now directly owns 40,354 shares of the company’s stock, valued at $5,192,349.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Edward Miller sold 367 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $128.32, for a total value of $47,093.44. Following the sale, the senior vice president now directly owns 16,519 shares in the company, valued at $2,119,718.08. The disclosure for this sale can be found here. 4.41% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock valued at $128,153,000 after buying an additional 35,267 shares during the last quarter. Gateway Investment Advisers LLC boosted its position in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares in the last quarter. Brown Advisory Inc. boosted its position in Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares in the last quarter. Strs Ohio boosted its position in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares in the last quarter. Finally, MAI Capital Management boosted its position in Alexion Pharmaceuticals by 46.5% in the second quarter. MAI Capital Management now owns 4,281 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 1,358 shares in the last quarter. 96.34% of the stock is currently owned by institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.